Evidence map›Paper›PMID 35602879›Full record

ArticleAACE clinical case reports

Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism.

Krishnakumar Rajamani, Richard G Moore, Sheena M Stanard, Olga Astapova

Open access · goldAbstract readCase Reports
In one paragraph

Article in AACE clinical case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Krishnakumar RajamaniRochester Regional Health, 100 Kings Highway South, Rochester, New York.
Richard G MooreUniversity of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York.
Sheena M StanardRochester Regional Health, 100 Kings Highway South, Rochester, New York.
Olga AstapovaUniversity of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York.
Unity Health System · USUniversity of Rochester Medical Center · US

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Martha Susiarjo · 1985 to 2026
$42.8M
NIEHS NIH HHS P30 ES001247
6 · The paper itself

Abstract

Background/Objective: Epithelial cell ovarian carcinomas rarely secrete steroid hormones, while sex cord and stromal cell ovarian carcinomas often do so. The objective of this report is to describe a patient with endometrioid ovarian carcinoma, an epithelial cell tumor, who presented with hyperandrogenism due to testosterone production by the tumor. Case Report: A 67-year-old postmenopausal woman with no history of endometriosis presented with new onset of hirsutism. Her testosterone level was 282 ng/dL (8-60 ng/dL), estradiol level was 72 pg/mL (≤32.2 pg/mL), and 17-hydroxyprogesterone level was 592 ng/dL (≤45 ng/dL). Pelvic ultrasound showed a right adnexal mass measuring 14.7 × 9.7 × 12.3 cm and an endometrial thickness of 9 mm with calcifications within the endometrium. Human epididymis protein 4 level was 210 pmol/L (0-140 pmol/L), and cancer antigen 125 level was 144 U/mL (0-34 U/mL). The patient underwent exploratory laparotomy with removal of the pelvic mass. Pathology showed an endometrioid adenocarcinoma with positive immunohistochemistry staining for the following steroidogenic enzymes: side-chain cleavage enzyme, 17α-hydroxylase, and aromatase. There was no evidence of tumor metastases within the pelvic cavity. Ovarian tumor markers normalized and remained stable 1 year after surgery. Discussion: Although endometrioid ovarian carcinomas do not typically produce clinically significant levels of sex steroids, in rare cases, these tumors can do so, leading to symptoms and promoting early detection and treatment of the cancer. Conclusion: Sex hormone secretion by epithelial cell ovarian carcinomas should be considered in cases of new-onset steroid hormone excess in postmenopausal women.

Indexed as

cancerendometrioidepithelialovarytestosterone

Identifiers

PMID35602879
PMCPMC9123561
OpenAlexW4210395661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.